MEIP:NASDAQ $1.72, $2 per share cash excellent Phase 2 AML results
MEIP is the cheapest biotech on NASDAQ imo Incredible Phase 2 results for AML Phase 3 later this year Trades BELOW cash value SNSS had $500 MM market cap based on Phase 3 AML drug Very favorable writeup on SA this week: multiple catalysts Conference on Tuesday
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.